Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 study at the European Academy of Neurology Congress 2025, confirming that AJOVY (fremanezumab) is effective in ...
The final analysis showed similar overall survival, progression-free survival, and objective response rates, with no new safety signals identified compared with the primary analysis. The primary ...
HONG KONG, Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) is excited to announce that the final Overall Survival (OS) analysis results from the HARMONi-A study, a Phase III study evaluating ...
An Analysis of Ambient Air concentrations report was released Monday regarding the Bristol Virginia landfill by the Agency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback